POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Clinical Lymphoma, Myeloma & Leukemia(2023)

引用 0|浏览9
暂无评分
关键词
IBCL,SARS-CoV-2,tixagevimab-cilgavimab,breakthrough infection,hematological diseases,prophylaxis,immunocompromised patients,case
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要